Investor Relations

Investing in the Future of Human Health

Mojo BioPharma offers investors a unique dual-platform opportunity at the intersection of two of the most important frontiers in medicine — longevity science and precision oncology.

The Investment Thesis

Aging and cancer represent the two largest unmet medical needs of our time — and the two largest addressable markets in biopharmaceuticals. Mojo BioPharma's dual-division structure provides diversified exposure to both, with a pipeline anchored by differentiated science and a leadership team with a track record of value creation.

Differentiated Science

Klotho and antisense mRNA represent validated, high-conviction targets with strong preclinical and clinical proof-of-concept.

Dual-Platform Diversification

Two independent divisions reduce single-program risk while sharing operational infrastructure and scientific expertise.

Large Addressable Markets

Longevity therapeutics and oncology each represent multi-hundred-billion-dollar global market opportunities.

Experienced Leadership

Our team has navigated clinical development, regulatory approval, and capital markets across multiple programs.

Pipeline

Program Overview

DivisionCompoundIndicationStageNext Milestone

Longevity Sciences

MBP-101 (Klotho)Age-Related Systemic DeclinePreclinicalIND filing targeted

Longevity Sciences

MBP-102Neurodegeneration / Cognitive AgingDiscoveryLead optimization

Onco Sciences

SirexatamabSolid TumorsPhase IDose escalation ongoing

Onco Sciences

MBP-AS1 (Antisense mRNA)Hematologic MalignanciesPreclinicalIND-enabling studies

News

Press Releases

Press Release

Mojo BioPharma Announces Positive Sirexatamab Phase I Interim Data

October 2026

Conference

Company Presents Klotho Program Data at International Longevity Congress

September 2026

Press Release

Mojo BioPharma Closes Series B Financing to Advance Dual-Division Pipeline

August 2026

Get in Touch

Investor Inquiry

We welcome inquiries from qualified investors and strategic partners. Our investor relations team will respond within 2 business days.

Confidential treatment of all inquiries

Response within 2 business days

Access to investor materials upon qualification